Innovations Enable Packaging to Play Many Roles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovations Enable Packaging to Play Many Roles
Drug packaging performs functions such as ensuring patient well-being, providing information, preventing tampering, blocking counterfeiting, and improving compliance. Since 1977, packaging innovations have occurred in four major categories. The author provides an overview of major packaging improvements that have emerged in the past 30 years.


Pharmaceutical Technology


Package design deters counterfeiters when it is distinctive, difficult to duplicate, and incorporates features such as holographic labels, microprinting, color-shifting ink, or radio-frequency identification (RFID).


The "Clonidine" wallet pack combines child-resistant, senior-friendly, and compliance features.
Yet another way packaging enhances patient safety is by preventing medication mistakes. Simple design techniques such as color coding can flag crucial information such as dosage strength and administration method. The Association of Anaesthetists of Great Britain and Ireland (London) and three related organizations have developed guidelines for color coding self-labeled syringes used in critical-care areas to help identify drug and drug type at a glance.

In addition, FDA has mandated unit-of-use barcoding on the packaging of prescription and OTC drugs dispensed in hospitals. The barcode carries the product's National Drug Code and may also include a lot number and expiration date. Scanning with a barcode reader identifies the product and provides an automated means to confirm that the correct dose is being given to the right patient at the proper time through the correct administration route. If patient wristband information and caregiver identification is scanned, the system also can help automate record keeping and billing (4).

More than half of all prescriptions are not taken correctly (5). Reasons include difficulty remembering when to take a dose and whether a dose was taken. Creatively printed blister cards and presentations like wallet packs arrange medication in an organized fashion. Patients who take their medicine on schedule tend to experience more positive outcomes and lower healthcare costs. Increased compliance also generates sales for pharmacies and drugmakers because it encourages the prompt refill of prescriptions and the restocking of OTC drugs in the medicine cabinet (6).


Item-level radio-frequency identification tagging is moving from pilot projects to daily use, especially for commonly counterfeited products. Shown here are item-level tags and a reader from Impinj, Inc. (Seattle, WA).
One example of a sophisticated compliance package is a CR, senior-friendly wallet pack for "Clonidine" from Mylan Pharmaceuticals Inc. (Morgantown, WV) and UDL Laboratories, Inc. (Rockford, IL). The package was recently recognized in an annual competition sponsored by the Healthcare Compliance Packaging Council (Falls Church, VA). The design features a plastic housing with a slide-out drawer that holds a push-through blister card with 30 tablets arranged in four rows. Pressing a button unlocks the drawer so it can be pulled out to grant access to the medication. Precisely registered printing on the blister card indicates when each dose should be taken ("Shellpak" compliance package, MeadWestvaco Healthcare Packaging, New York).

Advances in materials and containers

Material and container advances help make design innovations a commercial reality, ensure products are adequately protected to maintain potency until the end of their expected shelf lives, simplify administration, minimize the chances of mislabeling or misdosing, discourage counterfeiting, and reduce the environmental impact of packaging.

Various materials can protect a product's shelf life. New combinations that offer good protection or low cost appear on the market constantly. Some innovations rely on familiar barrier materials such as "Aclar," ethylene vinyl alcohol, and polyvinylidene chloride. Others such as cyclic olefin copolymer (COC) and cyclic olefin polymer (COP) are newcomers to the pharmaceutical industry (7). COC replaces barrier-coated polyvinyl chloride (PVC), is capable of 5-in. draws, and forms on the same tooling as PVC. COP is compatible with injection-molded containers and flexible packaging, provides compatibility with ethylene oxide and gamma sterilization, and contains extremely low residual-metals content.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here